

# Recombinant SARS-COV-2 Spike S1 (D614G) Protein (His&Avi Tag)

Cat. No. bs-46010P

## Description

<b>Protein Sequence</b>	SARS-COV-2 Spike S1 (D614G) Protein is expressed with a His-tag and Avi at the C-terminal (Gln14-Arg683).
<b>Source</b>	Mammalian Expression System
<b>Accession</b>	QHD43416.1
<b>Mol wt</b>	The protein has a predicted MW of 77.9 kDa. Due to glycosylation, the protein migrates to 110-120KDa based on the Bis-Tris PAGE result.
<b>Endotoxin</b>	Less than 1EU per ug by the LAL method.
<b>Purity</b>	>95% as determined by Bis-Tris PAGE
<b>Activity assay</b>	Not tested.

## Formulation and Storage


<b>Formulation</b>	Lyophilized powder (Lyophilized from 0.22um filtered solution in 20mM PB (pH 7.4). 5% trehalose is added as protectant before lyophilization.)
<b>Storage</b>	The product should be stored at -70°C or -20°C.

## Background

The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.


## Assay Data

### Tris-Bis PAGE




Recombinant SARS-COV-2 Spike S1 (D614G) Protein on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

### HPLC Data



The purity of Recombinant SARS-COV-2 Spike S1 (D614G) Protein is greater than 95% as determined by SEC-HPLC.

### ELISA Data



Immobilized SARS-CoV-2 S1 (D614G) at 2µg/ml (100µl/Well) on plate. Dose-response curve for Human ACE2 with the EC50 of 42ng/ml determined by ELISA.

**Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.**